Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 5.84%. However, over the last six months, the performance has been stronger by -15.17%. The price of HALO decreased -15.97% over the last 30 days. And in the last five days, it has fallen by -14.78%.
Halozyme Therapeutics Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $70.50 on 05/07/25, while the lowest price for the same period was registered at $42.01 on 11/18/24.
52-week price history of HALO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Halozyme Therapeutics Inc’s current trading price is -28.23% away from its 52-week high, while its distance from the 52-week low is 20.45%. The stock’s price range during this period has varied between$42.01 and $70.50. The Halozyme Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 7.07 million for the day, a figure considerably higher than their average daily volume of 1.74 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Halozyme Therapeutics Inc (HALO) has experienced a quarterly decline of -11.73% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.24B and boasts a workforce of 350 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 57.81, with a change in price of +1.12. Similarly, Halozyme Therapeutics Inc recorded 1,637,812 in trading volume during the last 100 days, posting a change of +2.33%.
HALO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HALO stands at 3.13. Similarly, the long-term debt-to-equity ratio is also 3.13.
HALO Stock Stochastic Average
As of today, Halozyme Therapeutics Inc’s raw stochastic average for the last 50 days stands at 4.69%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 4.69%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 47.90% and 67.52%, respectively.
